TD Asset Management Inc Purchases 4,256 Shares of Ascendis Pharma A/S $ASND

TD Asset Management Inc raised its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 1.5% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 296,346 shares of the biotechnology company’s stock after purchasing an additional 4,256 shares during the period. TD Asset Management Inc’s holdings in Ascendis Pharma A/S were worth $58,917,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the business. First Horizon Advisors Inc. bought a new stake in shares of Ascendis Pharma A/S during the second quarter worth approximately $41,000. Jones Financial Companies Lllp grew its holdings in Ascendis Pharma A/S by 57.2% during the 3rd quarter. Jones Financial Companies Lllp now owns 228 shares of the biotechnology company’s stock worth $44,000 after acquiring an additional 83 shares during the period. Hantz Financial Services Inc. lifted its stake in shares of Ascendis Pharma A/S by 291.1% in the 2nd quarter. Hantz Financial Services Inc. now owns 352 shares of the biotechnology company’s stock valued at $61,000 after purchasing an additional 262 shares during the period. Farther Finance Advisors LLC lifted its stake in shares of Ascendis Pharma A/S by 115.3% in the 3rd quarter. Farther Finance Advisors LLC now owns 478 shares of the biotechnology company’s stock valued at $95,000 after purchasing an additional 256 shares during the period. Finally, Toth Financial Advisory Corp boosted its position in shares of Ascendis Pharma A/S by 33.7% in the 3rd quarter. Toth Financial Advisory Corp now owns 595 shares of the biotechnology company’s stock worth $118,000 after purchasing an additional 150 shares during the last quarter.

Wall Street Analyst Weigh In

ASND has been the subject of a number of recent analyst reports. Wells Fargo & Company upped their price objective on Ascendis Pharma A/S from $322.00 to $330.00 and gave the company an “overweight” rating in a report on Tuesday, January 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Ascendis Pharma A/S in a research report on Wednesday, January 21st. Wedbush upped their price target on Ascendis Pharma A/S from $240.00 to $273.00 and gave the company an “outperform” rating in a research note on Thursday, February 12th. Royal Bank Of Canada lifted their price objective on shares of Ascendis Pharma A/S from $245.00 to $250.00 and gave the stock an “outperform” rating in a research note on Tuesday, January 20th. Finally, Wall Street Zen cut shares of Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a report on Saturday, November 15th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Ascendis Pharma A/S has an average rating of “Buy” and an average target price of $284.00.

Ascendis Pharma A/S Stock Performance

NASDAQ ASND opened at $228.99 on Friday. The stock has a market cap of $14.19 billion, a price-to-earnings ratio of -52.04 and a beta of 0.44. The business has a 50 day simple moving average of $218.56 and a 200 day simple moving average of $207.88. Ascendis Pharma A/S has a 52-week low of $124.06 and a 52-week high of $242.00.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings results on Wednesday, February 11th. The biotechnology company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.58). The firm had revenue of $290.38 million for the quarter, compared to the consensus estimate of $285.35 million. On average, analysts predict that Ascendis Pharma A/S will post -4.34 EPS for the current year.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.